Trusted Press Release Distribution   Join | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Fact.mr
www.factmr.com/
info@factmr.com
35316111593
Suite 9884 27 Upper Pembroke Street, Dublin 2


Bookmark and Share
Tuberculosis Biomarkers Market Forecast, Trend Analysis - Global Review 2017 to 2027
The development of biomarkers that can measure responsiveness to treatments and those that assess the risk of developing into full-fledged disease are critical clinical endpoints.

BriefingWire.com, 8/10/2018 - Tuberculosis (TB) biomarkers occupy a central role in the disease characterization, infection and risk assessment, rapid diagnosis, and ultimately cure. Despite considerable volumes of research and the proliferation of biomarker candidates over the past decades, the global tuberculosis biomarkers market is still characterized by large unmet needs. This is evident in the devastating effect of tuberculosis on the mortality and morbidity in worldwide populations. The market is replete with tuberculosis biomarkers that claim to measure the status of infection and further predict outcomes of vaccination or therapy. But, the fact that none of them is efficacious enough to enable a simple, accurate, and rapid diagnostic test for the infectious disease is a pressing concern.

Request TOC of this Report@ https://www.factmr.com/connectus/sample?flag=T&rep_id=569

The development of biomarkers that can measure responsiveness to treatments and those that assess the risk of developing into full-fledged disease are critical clinical endpoints. Hence, the development and launch of biomarkers that can measure well against such clinical endpoints is the need of the hour, belittling the massive investments made by companies so far. Hence, there is a need for more research that looks into reducing the gap between an emerging panoply of biomarker candidates and their efficacy against targeting product profiles. The need for non-DNA biomarkers to achieve this goal could unlock new, exciting avenues in the tuberculosis biomarkers market.

Tuberculosis biomarkers Market: Drivers and Restraints

Tuberculosis biomarkers market primarily driven by a key factors such as the increasing incidence of tuberculosis. According to the WHO, in 2016 approximately 1.7 million people were dead and 10.4 million new cases were reported, worldwide. The introduction of newer tuberculosis biomarkers is expected to play a crucial role in helping scientist in the characterization and selection of suitable treatment strategies. For instance, in 2016 scientist from Oxford University identified new biomarkers for Tuberculosis (TB) which will provide valuable clues to assess whether potential new vaccines could be effective. The antigen detection technology and biomarkers discovery strategies are rapidly evolving, which is expected to fuel the Tuberculosis biomarkers market growth. Increasing awareness among doctors, patients and technicians in the developing countries would help in promoting the growth of market. However, more chances of experimental failure, ethical issues associated with the tuberculosis diagnosis and treatment, huge investment, time consumption, low validation and independent confirmation of biomarkers limits further development of tuberculosis biomarkers market.

To know more about the Tuberculosis biomarkers Market, Visit the link @ https://www.factmr.com/report/569/tuberculosis-biomarkers-market

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2013 Proserve Technology, Inc.